Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anastazja Poczta"'
Autor:
Anastazja Poczta, Piotr Krzeczyński, Maksim Ionov, Aneta Rogalska, Udo S. Gaipl, Agnieszka Marczak, Dorota Lubgan
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 22; Pages: 14258
Myeloablative therapy with highdoses of the cytostatic drug melphalan (MEL) in preparation for hematopoietic cell transplantation is the standard of care for multiple myeloma (MM) patients. Melphalan is a bifunctional alkylating agent that covalently
Autor:
Arkadiusz Gajek, Violetta Cecuda-Adamczewska, Małgorzata Łukawska, Joanna Tobiasz, Anastazja Poczta, Agnieszka Marczak
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Scientific Reports
Scientific Reports
Chemical modification of known, effective drugs is one method to improve chemotherapy. Thus, the object of this study was to generate melphalan derivatives with improved cytotoxic activity in human cancer cells (RPMI8226, HL60 and THP1). Several melp
Autor:
Anastazja Poczta, Piotr Krzeczyński, Joanna Tobiasz, Aneta Rogalska, Arkadiusz Gajek, Agnieszka Marczak
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 1760, p 1760 (2022)
International Journal of Molecular Sciences; Volume 23; Issue 3; Pages: 1760
International Journal of Molecular Sciences; Volume 23; Issue 3; Pages: 1760
Despite the continuous developments in pharmacology and the high therapeutic effect of new treatment options for patients with hematological malignancies, these diseases remain a major health issue. Our study aimed to synthesize, analyze in silico, a
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-16 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-16 (2019)
The present study investigated the effect of cladribine (CLA) and six of its derivatives containing a formamidine group at position 6 (CLA-FDM, CLA-FPAZ, CLA-FPIR, CLA-FPIP, CLA-FHEX, and CLA-FMOR) on acute promyelocytic, lymphoblastic, and acute mon